Despite not being utilized as considerably as other antidepressants in the therapy of
depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in …

Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the
oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine …

Propargylamines are a versatile class of compounds which find broad application in many
fields of chemistry. This review aims to describe the different strategies developed so far for …

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Alzheimer's disease (AD) has a complex pathophysiology that includes aggregation of
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …

In Alzheimer's disease (AD), memory impairment is the most prominent feature that afflicts
patients and their families. Although reactive astrocytes have been observed around …

The modern era of drug development for A lzheimer's disease began with the proposal of
the cholinergic hypothesis of memory impairment and the 1984 research criteria for A …

It is estimated that the prevalence rate of Alzheimer's disease (AD) will double by the year
2040. Although currently available treatments help with symptom management, they do not …

Monoamine oxidase inhibitors were among the first antidepressants to be discovered and
have long been used as such. It now seems that many of these agents might have …